Search
01/11/2024
Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU
Casanova, MJ, Caballol, B, García, MJ, Mesonero, F, de Célix, CR, Suárez-Alvarez, P, Ferreiro-Iglesias, R, Martín-Rodríguez, MDM, de Francisco, R, Varela-Trastoy, P, Bastida, G, Carrillo-Palau, M, Núñez-Ortiz, A, Ramírez-de la Piscina, P, Ceballos, D, Hervías-Cruz, D, Muñoz-Pérez, R, Velayos, B, Bermejo, F, Busquets, D, Cabacino, M, Camo-Monterde, P, Marín-Jiménez, I, Muñoz, C, de la Peña-Negro, LC, Sierra-Moros, E, Barrio, J, Brunet-Mas, E, Bujanda, L, Cañete, F, Gomollón, F, Manceñido-Marcos, N, Rodríguez-Lago, I, Rodríguez-Grau, MC, Sicilia, B, Torra-Alsina, S, Arranz-Hernández, L, Carpio, D, García-Sepulcre, MF, González-Muñoza, C, Huguet, JM, Márquez-Mosquera, L, López-Serrano, MP, Ponferrada-Díaz, A, Chaparro, M, Gisbert, JP. Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU. DIGESTIVE AND LIVER DISEASE. 2024; 56(11)DOI:10.1016/j.dld.2024.05.009. PMID:38839456. IF:3.800(Q2/3D).
01/10/2024
Examining the therapeutic landscape of beta-blockers in portal hypertension
Brujats, A, Villanueva, C. Examining the therapeutic landscape of beta-blockers in portal hypertension. Clinical and Molecular Hepatology. 2024; 30(4)DOI:10.3350/cmh.2024.0144. PMID:38447532. IF:16.900(Q1/1D).
01/10/2024
Persistent varices in cured patients: Understanding the role of hepatic venous pressure gradient
Olivas, P, Soler-Perromat, A, Tellez, L, Carrion, JA, Alvarado-Tapias, E, Ferrusquia-Acosta, J, Lens, S, Guerrero, A, Falga, A, Vizcarra, P, Orts, L, Perez-Campuzano, V, Shalaby, S, Torres, S, Baiges, A, Turon, F, Garcia-Pagan, JC, Garcia-Criado, A, Hernandez-Gea, V. Persistent varices in cured patients: Understanding the role of hepatic venous pressure gradient. Jhep Reports. 2024; 6(10)DOI:10.1016/j.jhepr.2024.101170. PMID:39430576. IF:7.500(Q1/2D).
01/10/2024
THE GLOBAL PROFILE OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD): CLINICAL PRESENTATION, HISTOLOGIC STAGE, NON-INVASIVE TESTS AND MORTALITY FROM THE GLOBAL NAFLD/MASLD REGISTRY
Younossi, Z, Alkhouri, N, Hagström, H, Kim, SU, Crespo, J, Castera, L, Zheng, MH, Treeprasertsuk, S, Shalimer, D, Alswat, K, Fan, JG, Roberts, S, Tsochatzis, E, Dunn, W, Wong, V, Yilmaz, Y, Francque, S, de Oliveira, C, Pessoa, MG, Ekstedt, M, Goh, GBB, Duseja, A, Chan, WK, Fernandez, MIC, Sebastiani, G, Lampertico, P, Alnaamani, K, Valsan, AK, Holleboom, AG, El-Kassas, M, Choudhary, NS, Vessby, J, Singal, A, Kakizaki, S, Pearlman, B, Gunn, N, Cordie, A, Mauricio, D, Kawaguchi, T, Nadeem, R, Shang, Y, Lee, HW, Iruzubieta, P, Liu, WY, Ananchuensook, P, Yang, RX, Zoncapé, M, Dunn, N, Song, SJ, Gadi, Z, Teh, KKJ, Mahadeva, S, Fabian, LG, Cinque, F, D'Ambrosio, R, Friend, E, Poca, M, Colombu, M, Allen, A, Lazarus, J, Lam, B, de Avila, L, Racila, A, Alqahtani, S, Stepanova, M. THE GLOBAL PROFILE OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD): CLINICAL PRESENTATION, HISTOLOGIC STAGE, NON-INVASIVE TESTS AND MORTALITY FROM THE GLOBAL NAFLD/MASLD REGISTRY. HEPATOLOGY. 2024; 80DOI:. PMID:. IF:15.800(Q1/1D).
01/09/2024
An artificial intelligence-assisted system versus white light endoscopy alone for adenoma detection in individuals with Lynch syndrome (TIMELY): an international, multicentre, randomised controlled trial
Ortiz, O, Daca-Alvarez, M, Rivero-Sanchez, L, Gimeno-Garcia, AZ, Carrillo-Palau, M, Alvarez, V, Ledo-Rodriguez, A, Ricciardiello, L, Pierantoni, C, Hüneburg, R, Nattermann, J, Bisschops, R, Tejpar, S, Huerta, A, Pons, FR, Alvarez-Urturi, C, López-Vicente, J, Repici, A, Hassan, C, Cid, L, Cavestro, GM, Romero-Mascarell, C, Gordillo, J, Puig, I, Herraiz, M, Betes, M, Herrero, J, Jover, R, Balaguer, F, Pellisé, M. An artificial intelligence-assisted system versus white light endoscopy alone for adenoma detection in individuals with Lynch syndrome (TIMELY): an international, multicentre, randomised controlled trial. Lancet Gastroenterology & Hepatology. 2024; 9(9)DOI:10.1016/S2468-1253(24)00187-0. PMID:39033774. IF:38.600(Q1/1D).
01/08/2024
Immune Response and Risk of Decompensation following SARS-CoV-2 Infection in Outpatients with Advanced Chronic Liver Disease
Brujats, A, Huerta, A, Osuna-Gómez, R, Guinart-Cuadra, A, Ferrero-Gregori, A, Pujol, C, Soriano, G, Poca, M, Fajardo, J, Escorsell, A, Gallego, A, Vidal, S, Villanueva, C, Alvarado-Tapias, E. Immune Response and Risk of Decompensation following SARS-CoV-2 Infection in Outpatients with Advanced Chronic Liver Disease. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2024; 25(15)DOI:10.3390/ijms25158302. PMID:39125872. IF:4.900(Q1/3D).
01/07/2024
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
Ruiz-Cobo, JC, Llaneras, J, Forns, X, Moya, AG, Amiel, IC, Arencibia, A, Diago, M, Garcia-Samaniego, J, Castellote, J, Llerena, S, Rodriguez-Seguel, E, Mateos, B, Rodriguez, M, Zabal, JMR, Fernandez, I, Calleja, JL, Morillas, RM, Montoliu, S, Andrade, RJ, Aranda, EB, Hernandez-Guerra, M, Mate, CJ, Gonzalez-Santiago, JM, de Cuenca, B, Bernal-Monterde, V, Delgado, M, Turnes, J, Lens, S, Buti, M. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir. ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2024; 60(2)DOI:10.1111/apt.18020. PMID:38695095. IF:6.700(Q1/1D).
28/06/2024
Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry
Ferreiro-Iglesias, R, Silva, SP, Marín, S, Casanova, MJ, Mañosa, M, González-Muñoza, C, de Francisco, R, Caballol, B, Arias, L, Piqueras, M, Zabana, Y, Rivero, M, Calvet, X, Mesonero, F, Trastoy, PV, Nistal, RB, Perosanz, RG, Vega, P, Gonzalez-Vivo, M, Iborra, M, Bermejo, F, Madero, L, Rodríguez-Lago, I, Gonzalez, MR, Vera, I, Díaz, AP, Vela, M, Medina, LT, Van Domselaar, M, Gomollón, F, Iglesias, E, Gisbert, JP, Calafat, M, Giordano, A, Pérez-Martínez, I, Ricart, E, Sicilia, B, Mena, R, Esteve, M, Rivas, C, Brunet-Mas, E, Fernández, C, Turrión, MAD, Jiménez, BV, Calvo, MQ, Expósito, CR, Márquez-Mosquera, L, Nos, P, Granja, A, Gutiérrez, A, Cabriada, JL, Cruz, DH, Calvo, M, Pérez, JP, Díaz, YR, Casal, DB, Menacho, M, Leal, C, Lucendo, AJ, Royo, V, Olivares, S, Herrero, BA, Carrillo-Palau, M, Alvarez, PG, Marcos, NM, Martínez-Pérez, TD, Villafranca, MCM, Almela, P, Argüelles-Arias, F, Legido, J, Coronel, AMF, Nieto, L, Domènech, E, Acosta, MBD. Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry. ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2024; 60(5)DOI:10.1111/apt.18133. PMID:38943230. IF:6.700(Q1/1D).